Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01710332 · ClinicalTrials.gov registry record · Phase 2
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
A Phase 2 study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT01710332: Completed Phase 2 study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
NCT01710332 is a Phase 2 study of Central Serous Chorioretinopathy that has completed, run by Wills Eye. The registered enrollment target is 12 participants, below the 87-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (86% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01710332, a Phase 2 study of Central Serous Chorioretinopathy, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Primary Outcome
Safety will be measured by the amount, significance and details of adverse events/reactions to the study drug.
Conditions Studied
Interventions
- DRUG Intravitreal Aflibercept Injection
Study Locations (2)
Pennsylvania
- Mid Atlantic Retina- Huntingdon Valley - Huntingdon Valley
- Mid Atlantic Retna- Wills Eye Institute - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 2 |
What the finished NCT01710332 record still lists
NCT01710332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 87-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 1 intervention - of which Intravitreal Aflibercept Injection is the first listed.
NCT01710332 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01710332 about?
NCT01710332 is a clinical study titled "The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy". A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
What is the current status of trial NCT01710332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2012-10. Estimated completion is 2013-06.
What conditions does trial NCT01710332 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT01710332?
The interventions under investigation include: Intravitreal Aflibercept Injection (DRUG).
Who is sponsoring clinical trial NCT01710332?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01710332 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
Eplerenone for the Treatment of Central Serous Chorioretinopathy
COMPLETED · NA
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia